George Church

But again, I don't think that'll be completely shocking.

But it's just going to be so much of it.

It's going to be lots of diversity of solutions.

I'm not even sure it's going to make sense.

But, yeah, 100x would not be completely surprising.

Combinations of drugs will be important.

Using them intelligently, there'll be a lot more.

Some drugs will affect everything.

So, for example, an age-related drug, that could impact every disease.

Right.

I'm not sure the number is going to matter so much as the quality and the impact and intersection and software that helps physicians and regular citizens make decisions.

Well, the cost curves are affected by new tools.

I mean, it's not just some automatic thing.

There is a big discontinuity between Sanger sequencing and nanopores and fluorescent next-gen sequencing.

And so, you know, I think sometimes it's a merger of two things.

So clearly AI merging with protein design causes a step function.

These step functions get smoothed out into kind of a smooth exponential, but there are lots of them.

The next set will probably be a merger of AI with other aspects of biology, like developmental biology, merger of developmental biology with manufacturing.

Conquering developmental biology, in other words, actually knowing how to make any arbitrary shape given, you know, DNA as the programming material.

I think that would be a big thing.